Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin <10g/dL). Patients (n=29; 18 RBC-transfusion dependent) received 0.5 mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients respond...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Newberry, Kate, Pemmaraju, Naveen, Jabbour, Elias, Zhou, Linghsa, Pierce, Sherry, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157096/
https://ncbi.nlm.nih.gov/pubmed/25047979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2014.06.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados